Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Figure 1

Endoscopic findings. (a) Gastroscopy at presentation revealed an ulcerative mass with raised margins along the lesser curvature extending from the lower body of the stomach to the antrum. (b) After completion of the 11th course of chemotherapy (capecitabine + CDDP + trastuzumab), the gastric tumor is decreased remarkably.

(a)

(b)